In This Article
- Service Corporation International (SCI)
- Carriage Services, Inc. (CSV)
- Absci Corp. (ABSI)
- Matthews International Corp. (MATW)
- Citizens, Inc. (CIA)
⚠ Volatility Notice: This article contains micro-cap and/or small-cap stocks (under $1B market cap). These companies tend to have lower trading volume and can experience significantly higher price volatility than large-cap stocks. Please exercise additional caution and conduct thorough due diligence before investing.
Service Corporation International (NYSE: SCI)
$82.36
Overall Grade6.1 / 10
Founded in 1962, Service Corporation International has grown through strategic acquisitions to become a dominant consolidator in the deathcare industry. The company operates through two primary business segments: Funeral Home Operations and Cemetery Operations...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E19.8
P/B6.8
P/S2.4
P/FCF16.4
FCF Yield+6.1%
Growth & Outlook
Rev Growth (YoY)+2.9%
EPS Growth (YoY)+3.8%
Revenue 5yr+2.0%
EPS 5yr-1.4%
FCF 5yr-0.4%
Fundamentals
Market Cap$11.4B
Dividend Yield1.8%
Operating Margin+22.4%
ROE+34.7%
Interest Coverage5.1x
Competitive Edge
- Deathcare is one of the few consumer businesses where the asset base cannot be replicated. Cemetery land in dense metros is effectively zoned out of existence, so SCI's 1,400-plus locations and roughly 490 cemeteries are a supply-constrained position that Carriage Services or StoneMor cannot build around.
- The preneed backlog is a multi-billion dollar deferred revenue pool that converts on a biological schedule rather than an economic one. It gives SCI something almost no consumer discretionary name has: revenue already contracted and paid for, indexed to trust investment returns.
- Clustering is the actual moat mechanism. Sharing embalming facilities, hearse fleets, and preparation staff across several homes in one metro means SCI's incremental cost per service is well below a single-location independent, which is why the acquisition math keeps working at 6 to 8x EBITDA.
- Dignity Memorial branding plus a national preneed sales force lets SCI sell transferable contracts across state lines, something a family-owned operator cannot offer a mobile customer base. That is a real distribution advantage in an industry where 80% of operators are still single-location.
By the Numbers
- Free cash flow of $4.53 per share converts at 1.18x net income while capex runs 1.14x depreciation, so SCI is funding maintenance and cemetery development in full and still generating more cash than it books as profit. Earnings quality is not the problem here.
- Preneed insurance-funded production jumped 18.4% to $858.4 million on a 36.7% contract surge to 164,591, and insurance-funded maturities rose 6.8% to $435.6 million. Today's insurance sales are tomorrow's funeral revenue, and the maturity line is already turning.
- Funeral gross profit rose 6.6% to $495.8 million in FY2025 after three straight years of decline, outpacing the 3.5% funeral revenue gain. Funeral margin is finally expanding again after the post-pandemic volume normalization dragged it down.
- The negative 61.6 day cash conversion cycle, with 73.5 days payable against 7.9 days receivable and 4.0 days inventory, means customers and suppliers finance the working capital. That structure is why operating cash flow runs 1.93x net income.
- Share count fell 3.4% over the year against stock compensation of just 0.42% of revenue, so the $403 million of repurchases is real shrinkage, not dilution offset. Buyback yield of 3.5% on top of a 1.8% dividend is roughly 5% handed back.
Risk Factors
- Funeral preneed trust-funded production collapsed 29.2% to $339.7 million and contracts fell 49.6% to 57,295, a far steeper drop than the dollar decline. Average contract value went up while unit volume halved, suggesting a deliberate shift of lower-value business to insurance funding rather than pure demand growth.
- Property and merchandise revenue, the cemetery pre-need core, has now declined four years running: down 0.1%, 0.6%, 0.8% and 1.3%. Total revenue growth is being carried entirely by Other Service Revenue, up 21.8% to $422 million, a much smaller and lower-visibility line.
- ROIC of 4.0% sits far below ROE of 34.7%, and the gap is pure leverage: debt is 3.32x book equity and net debt is 3.79x EBITDA. Tangible book value per share is negative $4.55, so every dollar of equity return rests on borrowed money and $1.2 billion of goodwill.
- Interest coverage of 5.1x on the trailing figure, with the report reading it at 3.8x, is thin for a business carrying $5.3 billion of debt against a current ratio of 0.53. Refinancing at higher coupons would eat directly into the EPS growth that buybacks are producing.
- Surety bonds outstanding sit at $493.8 million after a 53.2% jump in FY2024. These back preneed obligations that are not fully trusted, an off-balance-sheet claim on future cash that grew far faster than revenue over the same window.
Carriage Services, Inc. (NYSE: CSV)
$35.11
Overall Grade5.2 / 10
Carriage Services, Inc. is a provider of funeral and cemetery services and merchandise in the United States...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E13.7
P/B2.2
P/S1.5
P/FCF16.3
FCF Yield+6.1%
Growth & Outlook
Rev Growth (YoY)+2.4%
EPS Growth (YoY)-16.2%
Revenue 5yr+3.0%
EPS 5yr+19.4%
FCF 5yr-36.7%
Fundamentals
Market Cap$562M
Dividend Yield1.3%
Operating Margin+21.9%
ROE+17.3%
Interest Coverage-3.4x
Competitive Edge
- Funeral homes compete on local heritage, not price. A family that used the Smith name for three generations does not shop, which is why Carriage runs a decentralized model paying managing partners on local profit rather than imposing SCI-style central standardization.
- Cemetery interment rights are sold pre-need years before the service, creating a deferred revenue backlog that gives visibility competitors in most consumer services never get, plus trust assets that earn investment income.
- The seller pool is structurally favorable. Thousands of family-owned homes face succession with no heir willing to take 24-hour call, and Carriage, SCI and StoneMor are the only credible buyers with financing, which keeps entry multiples rational.
- Cremation, usually framed as the sector's enemy, is margin-neutral when paired with cemetery inurnment and memorial merchandise. Carriage's cemetery segment gives it a place to recapture the revenue a casket sale used to carry.
- Death volumes are close to non-cyclical and the 65-plus cohort grows for the next two decades. This is one of the few consumer discretionary listings where the demand curve is demographic arithmetic rather than sentiment.
By the Numbers
- ROIC climbed from 3.5% in FY2020 to roughly 10% today while revenue only compounded 4.1% a year, so the gain came from pricing, divesting weak locations and deleveraging rather than volume. That is the more durable kind of return improvement.
- Operating margin of 21.9% against a 35.1% gross margin means overhead runs just 11.7% of revenue. For a 160-plus location rollup, that SG&A discipline is what funds the interest bill.
- Free cash flow of $2.37 per share covers the $0.456 dividend nearly five times, a 19% FCF payout. Capex is 5.7% of revenue and largely maintenance, so the cash is real and repeatable rather than a stretched distribution.
- OCF/net income of 1.37x and FCF/net income of 0.84x sit comfortably above the level where earnings quality gets questioned, and the grading engine notes cash collected runs 1.9% of assets ahead of reported profit.
- Deathcare pre-need trusts and a 34-day DSO give a 22-day cash conversion cycle with almost no inventory risk (35x turns). Working capital is not a call on cash when volumes wobble.
Risk Factors
- Net debt of $547M against $506M of market cap means debt holders own more of this enterprise than equity holders. At 5.9x net debt to EBITDA, a 200 basis point move in refinancing cost consumes a meaningful slice of the $53M net income analysts model.
- Tangible book value per share is negative $12.34 against $17.72 reported book. Goodwill and intangibles are 34.7% of assets, so the 1.81x P/B is really a multiple on acquisition accounting, not hard assets.
- EPS fell 16.2% and FCF fell 17.2% over the last year even as revenue rose 2.4%. That reverses a 19.4% five-year EPS CAGR and says the margin and divestiture tailwind that drove FY2022 to FY2025 earnings has run out.
- Share count grew 1.5% last year while buybacks returned only 0.32%, and debt paydown yield is negative 2.2%. Total shareholder yield is negative 0.44%, meaning the balance sheet and SBC took back more than dividends handed out.
- EBITDA fell 8.3% year over year against a 6.1% three-year growth rate, yet analysts model $138M of FY2026 EBITDA. Consensus assumes the decline was a one-off; nothing in the trailing numbers confirms that yet.
Absci Corp. (NASDAQ: ABSI)
$9.45
Overall Grade3.8 / 10
Absci Corporation is a clinical-stage biopharmaceutical company that utilizes a data-first generative artificial intelligence platform to discover and develop biologic drugs. Headquartered in Vancouver, Washington, the company integrates AI with scalable wet-lab technologies to accelerate the creation of novel antibody therapeutics...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-14.5
P/B7.3
P/S1,152.5
P/FCF-16.5
FCF Yield-6.1%
Growth & Outlook
Rev Growth (YoY)-62.3%
EPS Growth (YoY)-14.9%
Revenue 5yr-22.1%
EPS 5yr-28.5%
FCF 5yr+16.7%
Fundamentals
Market Cap$1.6B
Dividend Yield-
Operating Margin-8,084.5%
ROE-57.7%
Interest Coverage-1,224.5x
Competitive Edge
- Absci pairs generative AI antibody design with its own wet lab, so model predictions get tested and fed back as proprietary training data. Pure software rivals such as Generate Biomedicines and Isomorphic Labs must buy or partner for that loop; Absci owns both ends.
- The de novo antibody design claim, creating binders against a target without starting from an existing antibody, is the one capability that would let Absci charge a real toll rather than compete on service pricing with CROs like WuXi Biologics.
- Owning wholly-owned programs like ABS-101 and ABS-201 alongside partnered work gives two monetization paths: milestone and royalty income that needs no capital, plus clinical assets that can be sold outright if the market reprices AI-enabled biotech.
- Big pharma partnerships act as third-party validation that is hard for a small cap to fake, since a partner's discovery team has to accept the designs into its own pipeline before any milestone is paid.
- Almost no fixed capital base and low debt means the company can be resized quickly if a program fails, unlike a manufacturing-heavy biotech that must carry idle plant through a downturn.
By the Numbers
- Net cash of $197M against $3.8M of total debt means the balance sheet is effectively unlevered, so the entire enterprise value is a bet on the pipeline, not a claim contested by lenders. A current ratio of 10.63x removes near-term financing distress from the equation.
- Cash burn is improving even as the loss stays large: FCF grew 22.8% year over year and EBITDA improved 9.5%, so the burn curve is bending. For a clinical-stage name, slowing burn buys optionality on timing of partnership deals.
- Capex is almost nothing at $0.006 per share, only 8% of depreciation and 0.8% of operating cash flow. Absci is renting capacity rather than building it, meaning almost every incremental dollar raised goes into programs rather than bricks.
- FCF to net income of 0.90 and OCF to net income of 0.89 tell you the reported loss is close to a real cash loss, with no large accrual games. Earnings quality is clean even though earnings are deeply negative.
- Analyst models point to revenue of $3.9M in FY2026 and $16.1M in FY2027, implying about 140% annual growth from the $2.8M filed in FY2025. Eight analysts cover the top line, so the estimate is not a single outlier.
Risk Factors
- Revenue fell 21% a year between FY2022 and FY2025 and 38% in the last filed year, so the collaboration revenue that once validated the platform is shrinking while the market cap sits near $1.84B. P/S of 1,177x versus a 5-year average of 92x prices a pipeline, not a business.
- Share count grew 25.8% in the last year and 55% a year between FY2020 and FY2025, giving a buyback yield of -9.6%. Even if the science works, existing holders are being diluted faster than most drug programs advance a phase.
- SBC of $18.3M is 6.5x trailing revenue of $2.8M and roughly 15% of the annual cash burn. That is real value transfer to employees funded by shareholders, and it compounds the dilution already running through the share count.
- Trailing operating loss of $120M against $197M of net cash implies roughly a year and a half of runway at current burn before another raise, which is why the 25.8% annual share growth is likely to repeat rather than moderate.
- ROIC of -181% and ROE of -57.7% are getting less bad rather than good: management scored 4.1/10 partly because ROIC only moved from -99% in FY2020 to -95% in FY2023. Nine years of platform investment has not yet produced a single dollar of profitable capital deployment.
Matthews International Corp. (NASDAQ: MATW)
$19.04
Overall Grade3.3 / 10
Founded in 1850 as a small engraving shop, Matthews International Corporation has evolved into a diversified manufacturer operating across multiple continents. The company's largest segment, Memorialization, is a leading B2B supplier to the death care industry, providing products such as caskets, upright granite monuments, cremation urns, and incineration equipment...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E-28.9
P/B1.7
P/S0.8
P/FCF-10.3
FCF Yield-9.8%
Growth & Outlook
Rev Growth (YoY)-31.8%
EPS Growth (YoY)-56.1%
Revenue 5yr-7.4%
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$601M
Dividend Yield5.4%
Operating Margin+6.3%
ROE-5.9%
Interest Coverage2.4x
Competitive Edge
- Memorialization is one of the most inelastic end markets in consumer discretionary. Deaths do not track GDP, funeral homes buy caskets and bronze markers on replenishment cycles, and Matthews has been the incumbent supplier to that channel since the 1850s.
- Bronze memorial plaques and granite monuments carry design, mold and inventory lock-in at the cemetery and funeral home level. Switching suppliers means re-cataloguing product lines across thousands of small independent operators, which is why Matthews and Hillenbrand's Batesville have split the market for decades.
- The SGK Brand Solutions separation into the SGK Inc. joint venture with Saic Chemical strips out the lowest-quality, most competitive part of the portfolio while leaving Matthews with a stake and cash. It converts a diversified conglomerate discount into two cleaner stories.
- Industrial Technologies holds dry electrode manufacturing equipment and calendering IP for battery production, including the arbitration award against Tesla. That is a genuine option on solid-state and dry-process battery scaling that no memorialization comparable carries.
- Cremation rates rising above 60% in the US is not purely a headwind: Matthews sells cremation equipment, urns and incinerators, so it captures revenue on both sides of the burial versus cremation shift, just at a lower dollar content per death.
By the Numbers
- EV/EBITDA of 10.0x sits 61% below the 5-year average of 25.9x while EBITDA still grew 2.4% year over year and compounded 12.7% over three years. The enterprise is being priced off the wreckage in reported net income, not off cash earnings.
- Trailing EBIT of $75.5m grew 88% year on year even as revenue fell 31.8%, which tells you the revenue decline is largely deconsolidation of the SGK brand business rather than pure demand loss. The remaining revenue base carries materially higher operating margin.
- Debt paydown yield of 23% dwarfs the 4.0% dividend and 0.9% buyback. Management is using the SGK transaction proceeds to shrink a $628m debt stack, which is the correct priority at 4.9x net debt to EBITDA and 2.4x interest coverage.
- Analyst estimates for FY2026 put EBITDA at $141m on revenue of $1.04B, a 13.6% EBITDA margin versus the roughly 10% implied on trailing revenue. The residual Memorialization and Industrial Technologies mix is the more profitable half of the old company.
- Book value per share of $15.49 against a $19.70 price gives a P/B of 1.28x versus a 5-year average of 2.13x, and the current ratio of 1.76x means near-term liquidity is not the binding constraint even with negative operating cash flow.
Risk Factors
- Operating cash flow is negative at $1.89 per share while EBITDA is positive, a gap that points to enormous working capital and one-time transaction drag. Free cash flow of negative $2.61 per share against a $1.07 dividend means the payout is currently funded by the balance sheet, not the business.
- Tangible book value per share is negative $1.35 against stated book of $15.49. Goodwill and intangibles are 64% of total assets combined, so a single impairment cycle at Industrial Technologies would erase a large share of reported equity and push debt/equity well past the current 1.25x.
- Interest coverage of 2.39x on $628m of debt is the real pressure point, not the 4.89x net debt to EBITDA headline. If EBITDA slips even 20% from here, coverage approaches covenant territory while the company is still paying out $33m a year in dividends.
- Days inventory outstanding of 107.5 drives a 101.8 day cash conversion cycle, and the quick ratio of 0.52 shows that over 70% of current assets are inventory, not cash or receivables. Granite monuments and caskets are slow-turning, capital-absorbing goods.
- Only two analysts cover the name, and their FY2026 EPS estimate of $0.51 against a $19.70 price implies 38.8x forward earnings. That is a demanding multiple for a business whose revenue is expected to be flat at roughly $1.04B across FY2026 through FY2028.
Citizens, Inc. (NYSE: CIA)
$3.55
Overall Grade2.6 / 10
Citizens, Inc. (NYSE: CIA) is an insurance holding company that provides life insurance and related protection products to individuals and small businesses...
Grades
Valuation
Profitability
Growth
Debt
Dividend
Valuation
P/E27.3
P/B1.2
P/S1.1
P/FCF19.4
FCF Yield+5.1%
Growth & Outlook
Rev Growth (YoY)+2.1%
EPS Growth (YoY)-8.7%
Revenue 5yr+1.4%
EPS 5yr-
FCF 5yr-
Fundamentals
Market Cap$182M
Dividend Yield-
Operating Margin+5.6%
ROE+5.0%
Interest Coverage-
Competitive Edge
- The international segment selling USD-denominated whole life to Latin American and Pacific Rim clients fills a genuine niche. Wealthy non-US individuals wanting dollar-based protection face limited options, creating natural switching costs.
- Zero goodwill on the balance sheet means no acquisition-driven impairment risk. The asset base is real, consisting of investment securities and policy reserves rather than purchased intangibles.
- Whole life and endowment products generate long-duration, predictable premium streams. Policyholder behavior in international markets tends toward lower lapse rates due to the dollar-denominated savings component.
- Operating in a heavily regulated industry with high barriers to entry. Licensing requirements across multiple Latin American jurisdictions create a distribution moat that new entrants cannot easily replicate.
By the Numbers
- Trading at 0.82x book value with tangible BV/share of $4.39 vs. $3.78 price, meaning you're buying the insurance book at a discount to liquidation value. For an insurer with no goodwill, this is meaningful.
- Net cash position of $17M on a $193M market cap (8.8% of market cap) eliminates refinancing risk entirely and provides optionality for capital deployment or reserve strengthening.
- FCF-to-net-income conversion of 1.29x signals high earnings quality. Cash generation exceeds reported profits, which is uncommon for life insurers and suggests conservative reserve accounting.
- Forward P/E of 12.7x vs. trailing 18.2x implies consensus expects ~43% earnings growth. PEG of 0.3 suggests the market is dramatically underpricing whatever growth trajectory the single covering analyst sees.
- SBC/revenue at just 0.78% is negligible dilution. Share count grew only 0.37% last year, confirming management isn't quietly eroding per-share economics through compensation.
Risk Factors
- EPS has compounded at negative 24% over 3 years and negative 32% over 5 years. The trailing P/E of 18x on a shrinking earnings base means you're paying more for less. Revenue flatlined while profits collapsed.
- EV/EBITDA of 50.9x is extreme for a life insurer, suggesting operating earnings power is very thin relative to enterprise value. This dwarfs the seemingly cheap P/B and P/S ratios.
- ROE of 4.9% is well below any reasonable cost of equity for a micro-cap insurer. At this return level, the company is destroying economic value even if accounting profits are positive.
- Revenue growth has been essentially zero for a decade (0.38% 10Y CAGR). With only one analyst covering the stock, there's minimal institutional scrutiny and price discovery is poor.
- Non-interest income declined 78% YoY, a severe drop that suggests investment portfolio losses or realized gains that won't repeat. This volatility in a key insurance income stream is a red flag.
